| BMC Cancer | |
| Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer | |
| Research Article | |
| Jose-Javier Sanchez1  Rafael Rosell2  Massimo Rugge3  Ignacio Rodriguez4  Alain Vergnenegre5  Miquel Angel Molina-Vila6  Ana Gimenez-Capitan6  Carlota Costa6  Miquel Taron7  Laura Bonanno8  Adolfo Favaretto8  Margarita Majem9  Cinta Pallares9  Bartomeu Massuti1,10  | |
| [1] Autonomous University of Madrid, Ciudad Universitaria de Cantoblanco, 28049, Madrid, Spain;Catalan Institute of Oncology, Barcelona, Spain;Cytology and Pathology, Università degli Studi di Padova, Via Gabelli 61, Padova, Italy;Department Obstetrics, Gynecology and Reproduction, Dexeus Universisty Hospital, av Sabino de Arana 5-9, Barcelona, Spain;Hospital du Cluzeau, 23, rue Larey, Limoges, France;Laboratory of translational Oncology, Pangaea Biotech, Sabino de Arana, 5-9, Barcelona, Spain;Laboratory of translational Oncology, Pangaea Biotech, Sabino de Arana, 5-9, Barcelona, Spain;Catalan Institute of Oncology, Barcelona, Spain;Medical Oncology 2 Unit, Istituto Oncologico Veneto I.R.C.C.S, Via Gattamelata 64, 35128, Padova, Italy;Medical Oncology Service, Hospital de Sant Pau, Sant Antoni Maria Claret, 167, Barcelona, Spain;Medical Oncology, General Hospital of Alicante, 11, Baeza, 03010, Alicante, Spain; | |
| 关键词: BRCA1; HERC2; Non-small-cell lung cancer; Platinum; Predictive markers; DNA repair; | |
| DOI : 10.1186/s12885-016-2339-5 | |
| received in 2014-04-01, accepted in 2016-05-06, 发布年份 2016 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
BackgroundBRCA1 is a main component of homologous recombination and induces resistance to platinum in preclinical models. It has been studied as a potential predictive marker in lung cancer. Several proteins modulate the function of BRCA1. The E3 ubiquitin ligase HERC2 facilitates the assembly of the RNF8-UBC13 complex to recruit BRCA1 to DNA damage sites. The combined analysis of multiple components of the pathway leading to the recruitment of BRCA1 at DNA damage sites has the potentiality to improve the BRCA1 predictive model.MethodsWe retrospectively analyzed 71 paraffin-embedded tumor samples from advanced non-small-cell lung cancer patients treated with first-line platinum based chemotherapy and measured the mRNA expression levels of BRCA1, RNF8, UBC13 and HERC2 using real-time PCR. The mRNA expression was categorized using median value as cut-off point.ResultsThe median progression-free survival of all 71 patients was 7.2 months whereas the median overall survival of the study population was 10.7 months. Among patients with low BRCA1 expression, the median PFS was 7.4 months in the presence of low HERC2 levels and 5.9 months for patients expressing high HERC2 levels (p = 0.01). The median OS was 15.3 months for patients expressing low levels of both genes and 7.4 months for those with low BRCA1 but high HERC2 (p = 0.008). The multivariate analysis showed that among patients with Eastern Cooperative Oncology Group performance status 0–1, the combined low expression of both BRCA1 and HERC2 clearly reduced the risk of progression (p = 0.03) and of death (p = 0.004).ConclusionsThese findings confirm the potentiality of integrated DNA repair components analysis in predicting the sensitivity to platinum in lung cancer. The study indicates a predictive role for HERC2 mRNA expression and paves the way for further refinement of the BRCA1 predictive model.
【 授权许可】
CC BY
© Bonanno et al. 2016
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202311096278255ZK.pdf | 538KB |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
PDF